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Abstract. Antiestrogens represent the first line of therapy
in the treatment of estrogen receptor-positive (ER+) breast
cancer patients. Unfortunately, up to 40% of patients develop
resistance associated with progression and frequently die for
metastatic breast cancer. The molecular events leading to
pharmacological resistance are not completely understood.
We attempted to verify in an experimental model the role
of cytoplasmic clusterin (CLU), a cytoprotective protein
found to be up-regulated in antiestrogen-resistant patients,
following neoadjuvant treatment with toremifene. The role of
cytoplasmic clusterin in modulating response to two
antiestrogens (toremifene and tamoxifen) was studied in two
ER+ anti-estrogen-sensitive cell lines (MCF-7, 734B) and one
ER+ antiestrogen-resistant cell line (T47D) using siRNA
strategy. Resistant cells were characterised by higher levels
of cytoplasmic clusterin than sensitive cells, and antiestrogen
treatments up-regulated clusterin levels in both sensitive
and resistant cell lines. Treatment with siRNA completely
abolished cytoplasmic clusterin expression in all cell lines,
but its down-regulation resulted in a significant decrease of
cell growth only in the resistant line. We therefore concluded
that: i) basal clusterin levels are higher in antiestrogen resistant
cells, ii) clusterin is up-regulated following antiestrogen treat-
ment independently of the sensitivity of the cell line, iii) down-
regulation of cytoplasmic clusterin restores sensitivity to
toremifene in the antiestrogen-resistant cell line. Such results
support the concept that targeting CLU could represent a
promising therapeutic strategy in association with anti-
estrogen treatment in breast cancer patients.
Introduction
Selective estrogen receptor modulators have been the most
frequently used treatment for estrogen receptor-positive
(ER+) breast cancer, and their introduction has significantly
contributed to the reduction of mortality observed in recent
decades. Nonetheless, up to 40% of patients under treatment
develop resistance associated to relapse or disease progression
and frequently die from metastatic breast cancer. In most
cases, resistance is not associated to loss of the receptor,
which still seems to play a role in regulating tumour growth
even in resistant tumours. The mechanisms of antiestrogen
resistance are complex and frequently due to post-translational
modifications of the estrogen receptor that occur as a
consequence of activation of other signalling pathways,
mainly supported by growth factors (1). Resistance has been
traditionally subdivided into de novo (intrinsic) and acquired
resistance. Not only the pre-existing molecular pattern of the
tumour is important for response to antiestrogen treatment,
but early treatment-induced modulations of cellular pathways
are important as well. This concept has been recently
demonstrated taking advantage of gene-profiling studies
associated to a neo-adjuvant clinical trial (2). By profiling
samples obtained from a study with primary treatment with
toremifene (3), we observed that genes associated with
response to treatment and genes whose expression was
modulated by the treatment are different and that treatment
response affects gene modulation. A higher number of genes
was modulated by treatment in non-responders compared
to responders including genes likely to represent molecular
hurdles for complete response to treatment and which may
be targeted for improving response. Among such genes,
we focused on clusterin, also known as apolipoprotein J,
testosterone-repressed prostate message-2 or sulphated
glycoprotein-2. CLU is involved in many physiological
processes, and its overexpression is associated with cell
survival and apoptosis (4) whose balance markedly influences
tumour progression and treatment resistance. The functional
ambiguity of this protein is explained by the existence of
two splicing variants coding for one prevalently nuclear
form (lacking exon II) and one cytoplasmic secreted form
respectively associated with apoptosis and survival. In
response to cell stress, clusterin is rapidly up-regulated, and
the increased nuclear 55 kDa form suggests an apoptotic
response, although the precise relationship with the cell death
mechanism is not understood. However, other studies have
clearly demonstrated that overexpression of clusterin is a
cytoprotective, pro-survival response of cells to stress. The
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latter mechanism is also supported by recent findings showing
that targeting cytoplasmatic clusterin may interfere with drug-
resistance processes mediated by cell survival proteins (5).
This approach appears to be particularly helpful in those
tissues which overexpress clusterin such as prostate (6),
breast (7), and lung (8). In this sense, pioneering studies in
prostate cancer showed that the use of antisense nucleotides
against clusterin was able to restore androgen - and chemo-
sensitivity. Similarly, in bladder and lung cancer cells, anti-
sense suppression of CLU resulted into a potentiation of
antiapoptotic effects by cisplatin and paclitaxel (9) and an
effective modulation of clusterin could also be achieved with
small interfering RNA molecules (10).
In the present study, we investigated the expression of
clusterin at a protein level in response to antiestrogen treatment
in three ER+ breast cancer cell lines (MCF-7, 734B and
T47D) characterised by a different response profile to anti-
estrogens and the effect of its down-regulation by siRNA
strategy on response to the antiestrogens toremifene (TOR)
and tamoxifen (TAM).
The finding that down-regulation of clusterin was able to
increase sensitivity to antiestrogens especially in the resistant
cell line (T47D) might indicate clusterin as a candidate target
to improve the response to antiestrogens and delay the
appearance of acquired hormone-resistance.
Materials and methods
Cell line cultures. The human breast cancer cell lines MCF-7,
734B and T47D were cultured in Dulbecco's minimum
Eagle's medium/F12, DMEM/F12 (Sigma-Aldrich, St. Louis,
MO, USA) without red phenol supplemented with 5% fetal
bovine serum (Cambrex Bioscience, Milan, Italy) at 37˚C
under 5% CO2. Cells were split at least once before starting
the experiments.
In order to analyse the expression level of clusterin
following antiestrogen treatments, the three cell lines were
seeded in 25-cm2 flask for 24 h and allowed to attach. The
day after, the medium was changed with DMEM/F12 with
5% stripped FBS supplemented with 4OH-toremifene (4OH-
TOR) and 4OH-tamoxifen (4OH-TAM) 10-7 M (Sigma-
Aldrich). Cells were maintained in this medium for 3 days
until harvested.
siRNA transfection. For transfection assays MCF-7, 734B, and
T47D cells were seeded in DMEM/F12 5% FBS in 25-cm2
flasks and allowed to attach. The next day, the culture medium
was aspirated and the cell monolayers were washed with 2 ml
of Opti-MEM (Gibco, Carlsbad, CA, USA) to remove all the
traces of serum and were preincubated with Lipofectamine
2000 reagent (Invitrogen-Life Technologies Inc., Carlsbad,
CA, USA) in serum-free medium Opti-MEM for 20 min
before adding siRNA oligonucleotides (25 nM), separately
diluted in the same medium (3 μg/ml Lipofectamine final
concentration).
The custom-synthesised siRNAs (Dharmacon, Research,
Inc., Lafayette, CO, USA), were: CLU-V, for the exclusive
down-regulation of the clusterin cytoplasmatic form, CLU-III,
for the down-regulation of both cytoplasmic and nuclear
forms and a scrambled of the BIRC6 gene as control siRNA. 
The sequences of the siRNAs were: CLU-III-siRNA,
5'-CUA AUU CAA UAA AAC UGU CdTdT-3' and 3'-
dTdTGAU UAA GUU AUU UUG ACA G-5'; CLU-V-siRNA,
5'-AUG AUG AAG ACU CUG CUG C-3' and 3'-UAC UAC
UUC UGA GAC GAC G-5'; control siRNA (scrambled of
BIRC6 gene), 5'-GCA GUA CAU GGU AUG AUU AdTdT-3'
and 3'-dTdTCGU CAU GUA CCA UAC UAA U-5'. BLAST
analysis showed that CLU-III and CLU-V siRNAs were
complementary to sequences of exons 9 and 2, respectively,
whereas no homology was found between control siRNA and
other known human genes. Since exon 2 is maintained only in
the transcript that codifies for cytoplasmic clusterin, CLU-V-
siRNA is able to down-regulate only this particular form.
Twenty-four hours after starting the incubation, the medium
containing the RNA duplex and Lipofectamine was replaced
with DMEM/F12 with 5% stripped fetal bovine serum (FBS)
and cells were treated with antiestrogens. 4OH-TOR and
4OH-TAM were prepared in 2x10-3 M stock solutions in
ethanol. All the experiments were repeated three times.
Proliferation assay. For proliferation assay, cells were
trypsinised, washed once with Dulbecco's phosphate-buffered
saline (DPBS) 1X and harvested. Cells growth was determined
by direct counting in a Burker chamber. The viable fraction
was determined by trypan-blue exclusion (Sigma-Aldrich).
Experiments were carried out in triplicate.
Western blotting. Cytosolic extracts were prepared using a
commercially available kit (Active Motif Inc., Carlsbad, CA,
USA) according to the manufacturer's instructions. For Western
blot analysis, 30 μg of cytosolic proteins was separated by
SDS-PAGE and transferred onto nitrocellulose membranes.
Membranes were blocked for 1 h in DPBS 1X, 0.1% Tween-20
with 5% w/v non-fat dry milk and incubated with primary
antibody against clusterin (1:500, sc-6419 goat; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and against ß-actin
(1:1000, 20-33 rabbit; Sigma-Aldrich). Membranes were
washed and incubated for 1 h at room temperature with
peroxidase-conjugated anti-goat (Santa Cruz Biotechnology)
and anti-rabbit (Amersham Biosciences Europe, Freiburg,
Germany) secondary antibodies (1:2000) for the detection of
clusterin and ß-actin, respectively. All the antibodies were
diluted in DPBS 1X, 0.1% Tween-20 with 5% w/v non-fat
dry milk.
Signals were detected by chemiluminescence reaction
(ECL, Amersham Biosciences Europe) according to the
manufacturer's instructions. The relative amounts of clusterin
protein were quantified by densitometric analysis and
normalised with respect to the ß-actin signal.
Statistical analysis. The two-tailed t-test was used to
compare the statistical significance of the differences of cell
number between all treated samples and controls. Only the
significant P-values (≤0.05) are indicated. The values are the
mean of three independent replicates.
Results
Biologic model. The three breast cancer cell lines chosen for
the study were characterised by different sensitivity profiles
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towards the two antiestrogens, toremifene and tamoxifen.
Indeed, after treatment with 10-7 M 4OH-TOR for 3 days in
medium supplemented with 5% FBS, MCF-7 cells diminished
to 70±19% of the control (P=0.002) and were defined as
sensitive, 734B cells were not significantly inhibited to
81±15% and were considered as non-exquisitely sensitive,
but still non-resistant, while T47D cells were defined as
resistant with a slight up-regulation of growth in the presence
of toremifene (109±15% of the control). Similarly, after a
treatment with 10-7 M 4OH-TAM for 3 days in the same
conditions, the growth of MCF-7 and 734B cells was inhibited
respectively to 62±4% (P=0.0001) and 74±24% (P=NS) of
the control while T47D showed an increase of proliferation
(117±11% of the control). The data are shown in Fig. 1A and
Table I.
Western blot analysis showed that the two non-resistant
cell lines were characterised by lower clusterin protein levels
compared to the resistant T47D cell line (Fig. 1B). The basal
expression of clusterin was 6 and 15 times greater in T47D
than in MCF-7 and 734B, respectively. Furthermore, in all
three cell lines clusterin expression increased following anti-
estrogen treatments, in particular following tamoxifen (4 times
higher after tamoxifen treatment in the sensitive cell line
MCF-7). 
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Figure 1. A, Growth assay of three human breast cancer cell lines (MCF-7, 734B and T47D) untreated and treated with 10-7 M 4OH-toremifene (4OH-TOR)
and 4OH-tamoxifen (4OH-TAM) for 3 days. Results are the mean of three independent experiments. Statistical significance: *P=0.002; **P=0.0001 with
respect to the control. B, Western blot analysis of clusterin expression (active form) of MCF-7, 734B and T47D breast cancer cell lines untreated and treated
with 10-7 M 4OH-TOR and 4OH-TAM for 3 days. The relative amount of clusterin was quantified and normalised to the corresponding levels of ß-actin.
Table I. Cell growth after 3 days of treatment: values represent
the percentages of the untreated control.
––––––––––––––––––––––––––––––––––––––––––––––––– 
Treatment MCF-7 734B T47D
––––––––––––––––––––––––––––––––––––––––––––––––– 
Control 100±14 100±11 100±4
Toremifene 10-7 M 70±19a 81±15 109±15
Tamoxifen  10-7 M 62±4b 74±24 117±11
––––––––––––––––––––––––––––––––––––––––––––––––– 
aP=0.02. bP=0.0001.
––––––––––––––––––––––––––––––––––––––––––––––––– 
791-798  12/9/08  12:37  Page 793
Silencing of clusterin. Silencing of clusterin was attempted
by RNA interference approach. Specific siRNA designed
against distinct exons of the genes were used. Transfection
efficiencies were measured for each cell line monitoring
green fluorescence protein plasmid internalisation by flow
cytometry.
To assess the possible effect of clusterin basal levels and
treatment-induced up-regulation of clusterin on sensitivity to
antiestrogens, we treated the cells with two different siRNAs
targeting distinct exons of the gene: siRNA CLU-III (targeting
the secreted anti-apoptotic and the nucler pro-apoptotic form)
and siRNA CLU-V (targeting only the secreted form).
The result of the silencing approach was monitored by
Western blotting. The 60 kDa clusterin precursor appeared
together on the blots, with a protein smear around 40 kDa
comprising the two alpha and beta dimers and their relative
glycosylated forms.
As seen in Figs. 2 (MCF-7 cells), 3 (734B) and 4 (T47D),
siRNA CLU-III and siRNA CLU-V were both able to
completely suppress cytoplasmic clusterin protein expression,
which showed no recovery at all even after 3 days. However,
a slightly less effective silencing was observed in the T47D
cell line, which expressed higher CLU protein levels especially
after treatment with antiestrogens, which in turn further
increased clusterin levels (Fig. 4).
The specificity of the effects exerted by our siRNAs is
evident by the absence of any effects on clusterin protein
expression when cells were treated with a control siRNA
(siRNACTRL) and by the absence of any effect on ß-actin
expression.
Cell growth after clusterin silencing in the non-resistant cell
lines. To determine whether reduction of clusterin protein
levels affected cell growth in the cell lines alone or in the
presence of 10-7 M 4OH-TOR (left panel of Figs. 2, 3 and 4)
or 10-7 M 4OH-TAM (right panel of Figs. 2, 3 and 4), cells
were pre-treated with siRNA CLU-III (upper panel Figs. 2, 3
and 4) or siRNA CLU-V (bottom panel Figs. 2, 3 and 4) and
grown in the presence of the antiestrogen for 3 days.
Cell growth was assessed by direct cell counting, and
to ensure that any effect on growth was in fact correlated
to a specific down-regulation of clusterin, the same cells
were extracted and used for verification of specific protein
down-regulation. Table II reports the data regarding the
proliferation assays for the three lines.
Cell growth results were expressed as percentages of
the control (i.e., cells treated with the transfecting agent
lipofectamine alone, but the untreated control is also reported)
using the mean values of at least three separate experiments.
siRNACTRL, which had no affect on precursor or mature CLU
α and ß isoforms, did not affect the growth of MCF-7 cells in
the absence or in the presence of toremifene or tamoxifen.
As shown in Table II, neither siRNA CLU-III or CLU-V
significantly inhibited growth of MCF-7 cells in the presence
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Figure 2. Growth assay of the MCF-7 human breast cancer cell line untransfected or transfected with 25 nM siRNACTRL, siRNA CLU-III (upper part) or siRNA
CL-V (lower part) and untreated or treated with 10-7 M 4OH-TOR (left part) and 4OH-TAM (right part) for 3 days. Values are the mean of three replicates. A
representative Western blotting image is shown for each assay.
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Figure 3. Growth assay of the 734B human breast cancer cell line untransfected or transfected with 25 nM siRNACTRL, siRNA CLU-III (upper part) or siRNA
CL-V (lower part) and untreated or treated with 10-7 M 4OH-TOR (left part) and 4OH-TAM (right part) for 3 days. Values are mean of three replicates. A
representative Western blotting image is shown for each assay.
Figure 4. Growth assay of the T47D human breast cancer cell line untransfected or transfected with 25 nM siRNACTRL, siRNA CLU-III (upper part) or siRNA CL-V
(lower part) and untreated or treated with 10-7 M 4OH-TOR (left part) and 4OH-TAM (right part) for 3 days. Values are mean of three replicates. A representative
Western blotting image is shown for each assay. Statistical significance: *P=0.046 and ***P=0.0001 with respect to samples treated with siRNACTRL; **P=0.032 with
respect to samples treated with siRNACTRL and toremifene.
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or in the absence of treatment, despite complete down-
regulation of the protein.
Fig. 3 reports the results for the 734B cells. Once again,
Western blotting results confirmed the absence of any effects
on clusterin protein levels after treatment of the cells with
siRNACTRL, whereas a complete down-regulation of clusterin
was obtained with both tested target siRNAs. Similarly to
that observed with MCF-7 cells, both antiestrogens triggered
an up-regulation of clusterin which was, however, completely
abolished by the silencing procedure. No significant effects
on cell growth was observed upon treatment with siRNACTRL,
but even the two target siRNAs did not significantly affect
cell growth in the absence or in the presence of antiestrogens.
As a consequence, the down-regulation of clusterin in MCF-7
and 734B, which express low levels of the protein, did not
influence cell growth and did not increase sensitivity to anti-
estrogens.
Cell growth after clusterin silencing in the resistant cell line.
Fig. 4 shows the same type of experiments in the case of
the T47D antiestrogen resistant cell line. Basal expression
levels of clusterin were very high and further increased after
treatment with toremifene and tamoxifen. Similarly to that
observed in the two hormone-sensitive cell lines, no inter-
ference of control siRNA was observed on protein expression
or on growth. However, down-regulation of clusterin affected
cell growth. In the presence of siRNA CLU-III, cell growth
dropped to 73% with respect to siRNACTRL (P=0.046), whereas
in the presence of siRNA CLU-V it dropped to 43% of the
control (P=0.0001).
Such growth down-regulation exerted by siRNAs was
also maintained in the presence of toremifene despite the fact
that antiestrogens up-regulate clusterin. When the cells were
treated with antiestrogens, neither toremifene nor tamoxifen
inhibited cell growth but rather caused a small stimulation.
However, when cells were subjected to cytoplasmic clusterin
silencing (through treatment with siRNA CLU-V), toremifene
was able to cause cell growth inhibition down to 56% of
control, represented by cells treated with toremifene and
siRNACTRL (P=0.032).
Discussion
Antiestrogens represent the first-line therapy in ER+ breast
cancer, but unfortunately about 40% of patients do not
respond or develop resistance, determining the failure of the
therapy. Although different mechanisms have been proposed
to explain the phenomena of resistance, its relatively frequent
occurrence represents a challenge for clinicians and still is
not completely understood. 
Different survival proteins, which are up-regulated after
cytostatic and cytotoxic treatments, have been considered as
potential targets to overcome the problem of resistance in
breast cancer, among them members of the BCL-2 protein
family, survivin, heat-shock proteins, Akt and clusterin.
One major bottleneck in understanding the mechanism of
tamoxifen resistance is the lack of clinical study material,
since tumour tissues treated with antiestrogens associated
with response information are difficult to obtain, especially
for gene expression profiling. 
In the present study, we chose to focus on the role of
clusterin in determining responsivity to antiestrogens based
on results we had previously obtained in a clinical setting (2).
By profiling breast tumour samples obtained from ER+ breast
cancer patients before and after treatment with neoadjuvant
toremifene, we observed that the treatment-modulated gene
expression varied as a function of clinical response. In
particular, many more genes were modulated in patients
with a poor response to the treatment than in those with an
objective clinical response. We speculated that among genes
exclusively modulated in non-responding patients, some may
reveal pathways involved in activation of compensative
survival/cytoprotective pathways or in resistance mechanisms.
Among such genes, we focused on clusterin because a link
between clusterin overexpression and resistance to andro-
genic withdrawal (6), radiotherapy and chemotherapy has
already been reported in prostate cancer (11), but also in
breast cancer cells treated with trastuzumab or paclitaxel
(7,12). Interestingly, in different tumour types, clusterin
overexpression has also been associated with disease
extension and progression or with hallmarks of aggres-
siveness like negative estrogen and progesterone receptor
status in breast cancer (13).
The cytoplasmic form of clusterin, when secreted, acts
like a cytoprotective protein but its specific function remains
unclear. It has been supposed that clusterin could have a
chaperone-like activity because it binds to toxic molecules in
the extracellular environment protecting cellular membrane
integrity. In support of this hypothesis, there is the evidence
that the clusterin promoter contains a sequence of 14 bp
recognised by the transcription factor heat shock factor 1 (14).
In contrast, nuclear clusterin, an alternative splicing product
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Table II. Cell growth after treatment with siRNAs and anti-
estrogens: values represent the percentages of Lipofectamine-
treated cells.
–––––––––––––––––––––––––––––––––––––––––––––––––
Treatment MCF-7 734B T47D
––––––––––––––––––––––––––––––––––––––––––––––––– 
Control 100±17 100±10 100±5
siRNA ctr 97±14 97±15 87±4
siRNA CL-III 84±16 77±18 73±7a
siRNA CL-V 96±10 64±23 43±6b
Toremifene 10-7 M 82±17 84±7 102±4
siRNA ctr + TOR 71±19 76±6 83±14
siRNA CL-III + TOR 48±12 80±22 64±14
siRNA CL-V + TOR 57±12 74±16 56±0.6c
Tamoxifen 10-7 M 69±12 85±19 107±4
siRNA ctr + TAM 67±7 83±19 81±16
siRNA CL-III + TAM 50±9 68±5 62±5
siRNA CL-V + TAM 48±12 68±14 72±7
–––––––––––––––––––––––––––––––––––––––––––––––––
aP=0.046 with respect to siRNACTRL. bP=0.0001 with respect to
siRNACTRL. cP=0.032 with respect to siRNACTRL in combination
with TOR.
––––––––––––––––––––––––––––––––––––––––––––––––– 
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lacking exon 2, functions as a pro-apoptotic protein, although
its specific role and expression in cancer cells remains poorly
defined.
In the present study, we investigated whether knockdown
of clusterin attained with two siRNAs specifically targeted at
the nuclear and cytoplasmic form (CLU-III) or exclusively at
the anti-apoptotic cytoplasmic secreted form (CLU-V) has an
effect on basal cell growth of three ER+ breast cancer cell
lines with a different sensitivity profile to antiestrogens. After
having demonstrated the feasibility of effectively down-
regulating clusterin, we asked whether such a modification of
cells could, in fact, alter their response pattern to treatment
with antiestrogens.
Effectiveness of the silencing procedure was checked
only on the cytoplasmic form, as this is the antiapoptotic
one likely to interfere with treatment to antiestrogens, after
separating nuclei from cytoplasm to avoid any contamination
by the nuclear pro-apoptotic form. We observed that resistant
breast cancer cells were characterised by higher protein
levels of secreted clusterin than the sensitive cell line. This
observation suggests that constitutive expression of clusterin
could be indicative of sensitivity to antiestrogen treatment.
Furthermore, we observed that clusterin levels increased
after treatment with antiestrogens, a finding already reported
in the literature in the case of other types of treatment (15),
paclitaxel or simply estrogen withdrawal. Such treatment-
induced up-regulation of clusterin was independent of the
constitutive sensitivity profile of the cell line as it occurred
consistently on all three cell lines, although to a lesser extent
in T47D cells. However, both siRNAs were effective in
almost completely down-regulating the clusterin protein
levels.
In the fairly sensitive cell line MCF-7, up-regulation of
CLU could be interpreted as an adaptive survival mechanism
adopted by the cell to counteract growth inhibition effects. In
fact, although MCF-7 cells were sensitive to toremifene and
tamoxifen (at different degrees depending upon the length of
the treatment), we were unable to observe any apoptosis (data
not shown). Such an up-regulation has already been observed in
other studies (16,17) and might represent a general mechanism
of defence of cancer cells towards cytostatic drugs. This
hypothesis is supported by other studies demonstrating that
clusterin is up-regulated during conditions of cell stress,
similarly to that observed in breast cancer cells following
trastuzumab treatment (7) and in prostate cancer cells after
androgen ablation (18). Moreover, it has been demonstrated
that overexpression of clusterin by stable transfection protects
human cancer cells from apoptosis induced by different
triggers, like radiotherapy (19) and tumour necrosis factor α
(15). In vivo, this adaptive overexpression could increase cell
survival, thereby promoting progression and acquisition of
genomic instability.
We then investigated whether silencing of clusterin could
influence cell proliferation and could increase the responsivity
of breast cancer cell lines to tamoxifen and toremifene. We
first observed that silencing of clusterin was sufficient to
cause a statistically significant inhibition of cell growth, but
only in the resistant cell line T47D expressing a high level of
the protein. Comparable effects were obtained using both
siRNAs, although the inhibition was stronger when only
the cytoplasmic and not the pro-apoptotic form was down-
regulated, as happens with the treatment with CLU-V.
Moreover, down-regulation of clusterin was able to restore
sensitivity to toremifene in the resistant cell line, and once
again the effects were more evident with siRNA CLU-V.
Unfortunately, we did not obtain the same increase in
sensitivity when T47D cells were treated with tamoxifen,
probably because of their higher resistance and stronger
up-regulation of clusterin by tamoxifen than toremifene.
In cells sensitive or only partially sensitive to antiestrogens,
which are characterised by lower levels of clusterin than
resistant cells, targeting of clusterin did not significantly
modify cell growth under basal conditions or increase cell
sensitivity to the treatment. We consistently observed a modest,
not statistically significant drop in cell growth when the
siRNA treatment was added to the antiestrogen. However, in
resistant cells, which exhibited high clusterin levels, down-
regulation of the latter was effective in modulating response
to treatment. Such results are in agreement with previous
studies showing that clusterin silencing enhanced sensitivity
to different therapies in distinct tumour types. After CLU
silencing through siRNA and antisense strategies, cervical
cancer cells expressing high levels of clusterin were reported
to become more sensitive to paclitaxel (20), whereas breast
cancer cells increased their response to the HER2-targeted
monoclonal antibody trastuzumab (7) and chemotherapy
(12).
In the present study, we demonstrated the feasibility of
directly identifying in clinical studies, by gene profiling, genes
which might represent good candidates for the improvement
of treatment efficacy. However, the biological validation of
one of these genes, clusterin, gave only partially successful
results, since in sensitive cell lines down-regulation of clusterin
did not improve treatment as expected. Nonetheless, the
observation that by down-regulating clusterin an ER+ cell
line resistant to selective estrogen receptor modulators could
be made sensitive to toremifene represents an interesting
contribution that should be prospectively confirmed by
determining clusterin expression in addition to ER before
starting treatment with antiestrogens. Such results, if confirmed,
could provide a rationale for modulating sensitivity to anti-
estrogens by combining traditional therapy with strategies
targeting clusterin in vivo. 
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